5439602026-01-012026-03-315439602026-03-315439602025-03-315439602025-04-012026-03-315439602026-01-012026-03-31in-capmkt:OtherExpenses1Member5439602026-01-012026-03-31in-capmkt:OtherExpenses2Member5439602025-04-012026-03-31in-capmkt:OtherExpenses1Member5439602025-04-012026-03-31in-capmkt:OtherExpenses2Member5439602026-03-31OtherNoncurrentFinancialAssetsDomain15439602026-03-31OtherNoncurrentAssetsDomain15439602026-03-31OtherNoncurrentAssetsDomain25439602026-03-31OtherNoncurrentAssetsDomain35439602026-03-31OtherCurrentFinancialAssetsDomain15439602026-03-31OtherCurrentAssetsDomain15439602026-03-31OtherNoncurrentFinancialLiabilitiesDomain15439602026-03-31OtherCurrentFinancialLiabilitiesDomain15439602026-03-31OtherCurrentFinancialLiabilitiesDomain25439602026-03-31OtherCurrentLiabilitiesDomain15439602026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15439602026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25439602026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35439602026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss45439602025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15439602025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25439602025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss35439602025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss45439602026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15439602025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15439602026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543960CONCORDBIONAINE338H01029CONCORD BIOTECH LIMITEDMain BoardEquity2025-04-012026-03-312026-05-292026-05-23INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-05-2915:00:002026-05-2916:24:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated32607960001534940003414290000705409000156702000-39620004777120008400001954390007396200002271760000114253000001142530000286481000-303960002560850000886445000000-17760008846690001326330001017302000887905000-32350001021415000-411100010461600018.468.46008.468.46Notes to the statement of consolidated financial results for the quarter and year ended March 31 2026 <BR> <BR> 1 The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on 29th May 2026. The Statutory Auditors of the company have carried out audit of the said results. <BR> <BR> 2 The audited consolidated financial results of the Group include information of wholly owned subsidiary Concord Lifegen Limited w.e.f 21st July 2025, subsidiary Stellon Biotech Inc. w.e.f 1st July 2025 and joint venture Concord Biotech Japan K.K <BR> <BR> 3 The figures for the quarter ended March 31 2026 and March 31 2025 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31 2025 and December 31 2024 respectively, which were subjected to limited review. <BR> <BR> 4 The Group is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard Ind AS 108 Operating Segment <BR> <BR> 5 On 21 November 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on management’s assessment including actuarial valuation, considering the best information available and ICAI guidance, the group has recognised an incremental liability of Rs. 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended 31 March 2026. The group continues to monitor the notification of final Central/State rules and related clarifications and will evaluate and account for any additional impact in the period in which such rules are notified or clarifications issued <BR> <BR> 6 Celliimune Biotech Private Limited that is incorporated on 15 January 2025 has been acquired by Concord Biotech Limited as on 2 April 2026. As at 31 March 2026 the company has invested Rs 1.2 Lakhs for acquisition of shares out of total consideration of Rs 66 Lakhs for this acquisition. Celliimune Biotech Private Limited became a wholly owned subsidiary on 2 April 2026. <BR> <BR> 7 The above consolidated financial results has been prepared in accordance with Indian Accounting Standards Ind AS notified under Section 133 of the Companies Act, 2013 read together with Companies Indian Accounting Standards Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India SEBI2025-04-012026-03-31AuditedConsolidated10548907000523553000110724600002543478000626063000-71283000017690480002832000744586000264914900076223260003450134000-327540003417380000862909000-87280008541810000256319900000029092000259229100055243600031447270002609059000-167680003162831000-1810400010461600012006599700024.7824.780024.7824.78Power and fuel297597000Others442023000Power and fuel1161993000Others1487156000785717300078159200039630002440400011651000364570008493720000064642000914014000577470001591530009846154000326356100040206370004601971000121860000139300000252401000901079900002267570001250111700000223472710001046160002006599700020170613000-192330002015138000000001433400014334000371970004535890000505120000014749500087159900010190940004358630001454957000123379000112343000920000169077100000219589100022347271000Other Financial Assets64642000Prepaid expenses49211000Capital advances96117000Balances with government authorities13825000Other Financial Assets252401000Other Current Assets226757000Lease Liabilities14334000Other current financial liabilities427041000Lease Liabilities8822000Other current liabilities1233790002832000-8668890007045290000-84930000001424450000-8519800001019300007445860000497170000-90950000-1094810000246290000-959640000-1154430000-717400002554990003672879000000100406600002668813000012100088240880009468000000000009515110001003000000000000015447200011144000000002397700000-14272360000000000003811000554600011193930001200000-112876200011281500001128150009045000121860000Re-measurement gain/ (loss) on defined benefit plans-6875000Income tax relating to re-measurement gain/ (loss) on defined benefit plans1730000Fair value changes on equity investments through OCI168542000Income tax relating to fair value changes on equity investments through OCI-27263000136134000Re-measurement gain/ (loss) on defined benefit plans-16224000Income tax relating to re-measurement gain/ (loss) on defined benefit plans4083000Fair value changes on equity investments through OCI668709000Income tax relating to fair value changes on equity investments through OCI-9878700055778100035010005345000Items that will be reclassified to profit or loss00Items that will be reclassified to profit or loss0000132633000552436000AuditedtrueB S R & Co. LLPtrue2028-07-31